Rapid Production of Bispecific Antibodies Using Off-the-Shelf IgG

Similar documents
Site-Specific Bioconjugation Approaches for the Preparation of Novel Bispecific Antibody Platforms

AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis

phab Amine and Thiol Reactive Dyes for Antibody Internalization Studies Nidhi Nath, Ph.D. Group Leader, Protein Analysis Promega Corporation

Applications of HTRF and Tag-lite Assays for HTP Antibody Screening

Antibody drug conjugate screening and characterization

Time-resolved interaction analysis on living cells: Comprehensive data generates new knowledge and better decisions

The SMARTag TM ADC Technology Platform

Discovery on Target. Short Course Preview Deck

Supplementary Information. Human Antibody-Based Chemically Induced Dimerizers for Cell Therapeutic Applications

Western-GUARANTEED Antibody Service FAQ

Control Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design!

Antibody-Drug Conjugate Characterization and Quality Assurance

Oncology Product and Platform Partnering Opportunity

The United States Pharmacopeia Strategy on Biotherapeutic Products Standards. Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts

TITLE: Cell-penetrating Bispecific Antibodies for Targeting Oncogenic Transcription Factors in Advanced Prostate Cancer

Fusion Antibodies. Genes to Proteins to Antibodies

Perform reproducible immunoprecipitation in less than 40 minutes

Antibodies (Recommended reading: Abbas et al., 4th edition, Chapter 3; Chapter 4; Janeway et al., 5th edition, Chapter 3)

Linker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.

Recruitment of Grb2 to surface IgG and IgE provides antigen receptor-intrinsic costimulation to class-switched B cells

Xpress CF+ : A Cell-Free Platform for the Rapid Screening and Production of Homogeneous ADCs

Streamline Your Antibody Enrichment Using Scalable Magnetic Bead-Based Chemistries

Challenges in Bioassay Development for ADCs and Their Utility for Measuring In-vitro Activity of Conjugate Variants

How to Screen a Billion Drug Candidates?

Towards an in vivo Stability Assay for ADCs and Their Metabolites in Serum by Affinity Capture LC-MS

Structure of IgG and IgM

OX40 MARKET LANDSCAPE

ProteoGenix. Life Sciences Services and Products. From gene to biotherapeutics Target Validation to Lead optimisation

Introduction of Development Center for Biotechnology TAIWAN

Peptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST

Antibody Generation: challenges and solutions. Glen Marszalowicz, PHD May 10, AM

nanoprecipitation mpeg-pla 2 nd Emulsion mpeg-pla in DCM

Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages

Methods to Determine the Binding of Bevacizumab to Fc receptors

Euro Diagnostica ilite Cell-based Reporter Gene Assays

Novel Cell-Based Assays to Accelerate Cancer Immunotherapies. Abhi Saharia, Ph. D. Director, Cell-Based Assays

The Promise of DARPins for Site-Specific Drug Conjugation & Pharmacokinetic Optimization

Implementation of the Next Generation Effector Function Assays for Comparability Assessments

The Trianni Mouse: Best-In-Class Technology for Human Antibody Discovery

Nature inspired design of motif specific antibody scaffolds *

Ultrasound Contrast Agents for Molecular Imaging

Exceptional Human Antibody Discovery. Corporate Overview

Investigations in Immune Suppression for Monoclonal Antibody Therapeutics

Technical Challenges in the Development of Biosimilars. E. Morrey Atkinson, PhD Interphex May 1, 2012

MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. ***NOTE: Exam will have 40 multiple choice questions.

a. Hypoxanthine was present in the media. MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No.

CBI Toolbox Tour 2015

Protein or Peptide Antigen?

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion

Species predicted to react based on 100% sequence homology: Chicken, Bovine, Dog.

Data Sheet CD137/NF-κB Reporter - HEK293 Recombinant Cell Line Catalog # 79289

BioBA High Capacity Enrichment Sample Preparation Kit:

Surfaces with added value: Bioengineering for Bioanalysis and Medicine

Genes to Proteins to Antibodies

INVESTIGATION OF THE BINDING SPECIFICITY OF IGF-IR USING MONOCLONAL ANTIBODIES

ENCODE DCC Antibody Validation Document

Process Development for a Peptide Conjugated QbetaVirus Like Particle (VLP) Vaccine

How to HRP Label and Purify Your Antibody - No HPLC Needed.

Quality attributes impacting immunogenicity of therapeutic proteins

Application of Biacore Technology

MagSi Beads. Magnetic Silica Beads for Life Science and Biotechnology study

Make High Quality Affordable

IMPROVE SPEED AND ACCURACY OF MONOCLONAL ANTIBODY BIOANALYSIS USING NANOTECHNOLOGY AND LCMS

TITLE: Engineering Anti-EGFR Antibodies for Treatment of Breast Cancers with Poor Prognosis

Newsletter Issue 7 One-STrEP Analysis of Protein:Protein-Interactions

Tracking Cellular Protein Localization and Movement in Cells with a Flexible Fluorescent Labeling Technology. Chad Zimprich January 2015

Thermo Scientific MAbPac HIC Columns. Novel Hydrophobic Interaction HPLC Columns. Designed for Monoclonal Antibody Analysis

Regulatory Perspectives on Higher Order Structure Evaluations for Protein Products. Emily Shacter, Ph.D.

Study Small Molecule-Membrane Protein Binding Kinetics with. Nanodisc and Charge Sensitive Optical Detection

PROF. DR. ASMAA HUSSEIN DIRECTOR OF THE MOLECULAR BIOLOGY RESEARCH UNIT

Custom Antibodies & Recombinant Proteins

Real-time 96-well antibody internalization assays using IncuCyte FabFluor Red Antibody Labeling Reagent

SUMOstar Gene Fusion Technology

Molecular Magnetic Resonance Imaging of Tumor Response to Therapy

Application Note AN001

Quantitative And Spatial Optimization Of Therapeutic Fusion Proteins

Analysis of receptor oligomerization by FRAP microscopy

Basic Antibody Structure. Multiple myeloma = cancerous plasma cells Monomer = 150,000. Chapter 4. Immunoglobulin Structure and Function

Immunological Techniques in Research and Clinical Medicine. Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016

Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016

What s the difference? Challenges in pre-clinical development of biologics

Discover more with FluoroSpot

Building a deep immuno-oncology portfolio in less than a year. David Johnson, PhD PEGS Spring 2018

Overview of Solulink Products. June 2011

TARGETS Anti-Biotin Anti-Streptavidin Anti-FITC Anti-Phycoerythrin Anti-Mouse IgG Anti-Rabbit IgG (H+L) Anti-Human IgG (H+L)

B-cell Epitope Prediction and Cloning monoclonal ADAs

Supplementary Information for Structural and Mechanistic Insights into Cooperative Assembly of Dimeric Notch Transcription Complexes

Drug Tolerance in ADA Analysis

Regulatory perspective on setting clinically relevant specifications. Joslyn Brunelle, PhD Team Leader Office of Biotechnology Products

Peptide arrays for multiplex kinetic measurements Robust Instrumentation User friendly software

3D Structure of Biologics in a Convenient Immunoassay Format

Potelligent CHOK1SV. How It Works. Potelligent CHOK1SV

Overcoming drug & target interference in ADA and nabassays

Protein sorting at surfaces: Parallel affinity capture to patterns

PAVING THE WAY FOR ASSESSING IN VIVO DYNAMICS OF MULTIPLE QUALITY ATTRIBUTES FOR PROTEIN THERAPEUTICS

ADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies

Discovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A

SUPPLEMENTARY INFORMATION. Tolerance of a knotted near infrared fluorescent protein to random circular permutation

Transcription:

Rapid Production of Bispecific Antibodies Using Off-the-Shelf IgG Andrew Tsourkas, Ph.D. Professor Department of Bioengineering University of Pennsylvania

Limitations/Challenges of Nanoparticle Bioconjugations Conventional Chemistries are inefficient (typically <10%) and are not site-specific Click-chemistries are efficient, but are not-specific & require labeling of antibody

Creating Targeted Nanoparticles Targeting Group Crosslinker Contrast Agent/Nanoparticle HOOC NH 2 Desirable attributes for nanoparticle-targeting ligand conjugations Ability to work with any off-the-shelf antibody Highly efficient Site-specific/proper orientation on nanoparticle surface No effect on antibody affinity

Sortase-Tag Expressed Protein Ligation (STEPL) Site-specific C-terminal modification of any single-chain recombinant protein with any desirable tag (imaging agents, drug, peg, click moieties, etc.) % Protein Ligated % Peptide Utilized

Proximity-Based Sortase Ligation (PBSL) Binding partners are used to bring Sortase and Sortase Recognition Motif into close proximity, to increase the efficiency of ligation.

Proximity-Based Sortase Ligation (PBSL) Binding partners are used to bring Sortase and Sortase Recognition Motif into close proximity, to increase the efficiency of ligation.

Improving Nanoparticle Bioconjugations Confirmation of Click conjugation Magnetically purified SPIO are fluorescently labeled Cancer cells labeled with Her2-SPIO exhibit a a lower T2 Ligand density has large effect on avidity

Improving Nanoparticle Bioconjugations Her2-SPIO can be used to effectively detect Her2/neu-positive tumors

Rapid Production of Modular Bispecific Targeting Ligands Two affibody constructs were used to make 8 different bispecific targeting ligands

Improved Specificity of Bispecific Targeting Ligands Bispecific targeting ligands can be used to acquired enhanced specificity for double-positive target cell lines

Site-Specific IgG-Nanoparticle Conjugations EPL-Click can be combined with the incorporation of unnatural amino acids to allow for the site-specific attachment of IgG to nanoparticles.

Site-specific Modification of IgG Photoreactive Antibody binding domains (pabbds) bind at the C H 2-C H 3 hinge pabbds efficiently crosslink a wide range of antibodies from various hosts and subclasses

Optimization of IgG Bioconjugations pabbds can be covalently linked to IgG very rapidly and efficiently. A 1:1 pabbd-to-igg heavy chain ratio is adequate for complete labeling

Modification of a Single IgG Heavy Chain Steps can be take to modify only a single IgG heavy chain with Protein Z/G. IgG modified with pabbds exhibit the same affinity for their target receptor as native IgG.

IgG-Nanoparticle Bioconjugations pabbds enables the covalent linkage of IgG to Nanoparticles

IgG-Nanoparticle Bioconjugations Imaging VCAM-1 in murine inflammation model

Alternative IgG-Bioconjugate Applications pabbds allow us to functionalize antibodies with a wide array of chemical and biological moieties for use in diverse applications

One-Step Production of Bispecific Antibodies pabbd-scfv fusions allows IgG-scFv bispecific antibodies to be produced in a single step. pabbdscfv Bispecifics can be produced rapidly, in parallel, and with high purity

Affinity Assays Bispecific Antibodies - Bispecific antibodies exhibit no loss in affinity compared with the monoclonal antibody (mab) from which they are derived.

Bispecific Antibodies Exhibit High Potency Bispecific antibodies exhibit an EC50 of ~2 ng/ml (PMBCs, E:T = 10:1) Jeko B cells: Rituximab x anti-cd3 K562 cells: Rituximab x anti-cd3 Jeko B cells: Rituximab + anti-cd3 Jeko B cells: Rituximab

Rapid Production of Bispecific Antibodies from Two Full- Length IgGs Site-specific antibody conjugation methods can be used to make bispecific antibodies rapidly (<1 day) and efficiently

Cetux Cetux x Her Her Ritux Ritux x OKT3 OKT3 Her Her x OKT3 OKT3 Cetux Cetux x OKT3 OKT3 Rapid Production of Bispecific Antibodies 4 unique bispecific antibodies were generated by a one person in less than 24 hrs.

Rapid Production of Bispecific Antibodies Bispecifics exhibit similar affinity as individual wild-type IgG FPLC can be used to improve purity Trimer Dimer Monomer

Graduate Students Rob Warden James Hui Elizabeth Higbee Jessica Liu Post-Docs/Research Scientists Ching-Hui Huang Xumei Zhang Kido Nwe Yang Song Lesan Yan Jayesh Thawani Joel Stein Burcin Altun Acknowledgements Collaborators Zhiliang Cheng (Upenn) Vladimir Popik (UGa) Small Animal Imaging Facilities Weixia Liu Stephen Pickup Funding: NSF, NIH/NCI, NIH/NIBIB, American Cancer Society, CDMRP BCRP